| Ytd | -63.61% | |
| 1y | -65.15% |
| Open | 2.88 | Prev Close | 2.89 | Low | 2.85 | High | 2.90 | Mkt Cap | 26.76M |
| Vol | 53.59K | Avg Vol | 5.60M | EPS | -3.28 | P/E | -0.88 | Forward P/E | -0.87 |
| Beta | -0.68 | Short Ratio | 15.72 | Inst. Own | 42.68% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.27 | 200-d Avg | 5.45 | 1yr Est | 20.00 |
CRVO News
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy a
New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imag
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy a
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy a
CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-re
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo
Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar
On June 18, 2026, CervoMed Inc., a Delaware corporation (the "Company"), entered into a Secu
CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-re
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo
CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-r
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo
Explanation of Responses:1. On June 11, 2026, the Issuer completed a private placement (the "Pri
HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnolo
Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia wi
Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is
Continued progress towards initiating planned Phase 3 trial evaluating neflamapimod in patients with
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodeg
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global re
CIBC Private Wealth Group LLC cut its stake in Illumina, Inc. (NASDAQ: ILMN) by 4.1% in the third qu
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of dis
Illumina (NASDAQ: ILMN - Get Free Report) and CervoMed (NASDAQ: CRVO - Get Free Report) are both med
Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Es
Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTC
Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most
1st of two presentations with results from Phase 2b study of neflamapimod at the 18 th Clinical Tria
